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Abstract
We previously demonstrated that trans-10, cis-12 (10,12) conjugated linoleic acid (CLA) causes
human adipocyte delipidation, insulin resistance, and inflammation in part by attenuating PPARγ
target gene expression. We hypothesized that CLA antagonizes the activity of PPARγ in an isomer-
specific manner. 10,12 CLA, but not cis-9, trans-11 (9,11) CLA, suppressed ligand-stimulated
activation of a peroxisome proliferator response element-luciferase reporter. This decreased
activation of PPARγ by 10,12 CLA was accompanied by an increase in PPARγ and extracellular
signal-related kinase (ERK)1/2 phosphorylation, followed by decreased PPARγ protein levels. To
investigate if 10,12 CLA-mediated delipidation was preventable with a PPARγ ligand (BRL),
cultures were treated for 1 wk with 10,12 CLA or 10,12 CLA + BRL and adipogenic gene and protein
expression, glucose uptake, and triglyceride (TG) were measured. BRL cosupplementation
completely prevented 10,12 CLA suppression of adipocyte fatty acid-binding protein, lipoprotein
lipase, and perilipin mRNA levels without preventing reductions in PPARγ or insulin-dependent
glucose transporter 4 (GLUT4) expression, glucose uptake, or TG. Lastly, we investigated the impact
of CLA withdrawal in the absence or presence of BRL for 2 wk. CLA withdrawal did not rescue
CLA-mediated reductions in adipogenic gene and protein expression. In contrast, BRL
supplementation for 2 wk following CLA withdrawal rescued mRNA levels of PPARγ target genes.
However, the levels of PPARγ and GLUT4 protein and TG were only partially rescued by BRL.
Collectively, we demonstrate for the first time, to our knowledge, that 10,12 CLA antagonizes ligand-
dependent PPARγ activity, possibly via PPARγ phosphorylation by ERK.
Introduction
Dysfunction of adipose tissue can result in insulin resistance and lipodystrophy. One major
regulator in the development and function of adipose tissue is PPARγ, which induces the
expression of a host of adipogenic genes such as lipoprotein lipase (LPL), insulin-stimulated
glucose transporter 4 (GLUT4),5 perilipin (PLIN), and adipocyte fatty acid-binding protein
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and by the NIH (F31DK076208) to A.J.K.
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activated protein kinase; MEK, mitogen-activated protein kinase kinase; NFκB, nuclear factor kappa B; ORO, Oil Red O; PLIN, perilipin;
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(aP2). Mutations of PPARγ in humans are associated with insulin resistance and lipodystrophy
(1,2). PPARγ null cells exhibit impaired adipo-genesis (3) and dominant negative mutations
in PPARγ inhibit adipogenesis (4). Thus, PPARγ activity is essential in adipose tissue for
glucose uptake and triglyceride (TG) accumulation.
Regulation of PPARγ occurs through a variety of proposed mechanisms, including covalent
modification by phosphorylation, ligand binding, and heterodimerization with the retinoic acid
receptor (RXR) (5,6). Phosphorylation of PPARγ by activation of the mitogen-activated protein
kinase (MAPK) pathway has been reported to inhibit adipogenesis (7). It has been demonstrated
that phosphorylation of Ser-112 of PPARγ2 results in its ubiquination and proteosome
degradation (8). Activation of PPARγ by natural (i.e. PUFA) or synthetic ligands such as
thiazolidinediones (TZD) initiates heterodimerization with RXR followed by their binding to
peroxisome proliferator response element (PPRE) in the promoters of adipogenic target genes.
The TZD are hypoglycemics that activate PPARγ, leading to upregulation of adipogenic genes,
thereby enhancing insulin sensitivity. Natural ligands of PPARγ2 such as cis-PUFA or
prostaglandins such as PGJ2 (9) have a relatively low affinity for PPARγ compared with TZD.
In contrast, SFA and certain trans PUFA such as conjugated linoleic acid (CLA) have been
reported to impair insulin sensitivity, possibly by decreasing the expression of PPARγ and
many of its downstream target genes (10–13).
CLA consists of dienoic isomers of linoleic acid, including trans-10, cis-12 CLA and cis-9,
trans-11 CLA. CLA decreases body fat mass in animals (14) and some humans (15). Our group
has demonstrated that trans-10, cis-12 CLA decreases adipogenic gene expression and the TG
content of human (pre)adipocytes (10,11). We have also demonstrated that activation of MAPK
kinase (MEK)/extracellular signal-related kinase (ERK) (11) and nuclear factor κB (NFκB)
(16) signaling by trans-10, cis-12 CLA were essential for its suppression of adipogenic gene
expression and delipidation in human adipocytes. A number of side effects have been
associated with trans-10, cis-12 CLA supplementation in humans, such as insulin resistance,
hyperglycemia, and dyslipidemia (17,18). Dyslipidemia, insulin resistance, and hyperglycemia
are similar characteristics found in humans with mutations in PPARγ. Two recent reports by
Belury et al. (19,20) showed that the PPARγ agonist rosiglitazone prevents or attenuates
inflammation, lipodystrophy, and insulin resistance in mice fed a crude mixture of CLA
isomers containing equal amounts of cis-9, trans-11 CLA and trans-10, cis-12 CLA. However,
the isomer-specific mechanism by which CLA suppresses the expression of PPARγ and its
target genes in human adipocytes remains to be elucidated. To address this issue, we examined
the impact of CLA on PPARγ in the absence and presence of the PPARγ ligand rosiglitazone
(BRL).
Materials and Methods
Materials
All cell culture ware were purchased from Fisher Scientific. Western Lightning
chemiluminescence substrate was purchased from Perkin Elmer Life Science. The 1-step RT-
PCR kit used in semiquantitative mRNA analysis was purchased from Qiagen. Immunoblotting
buffers, precast gels, and gene-specific primers were purchased from Invitrogen and ribosomal
18S competimer technology internal standards and DNA-free were purchased from Ambion.
Polyclonal GLUT4 antibody was a gift from Drs. S. Cushman and X. Chen (NIDDK, NIH,
Bethesda, MD). aP2 antibody was a gift from Dr. D. Bernlohr (University of Minnesota).
Monoclonal antibodies for PPARγ (sc7273) and polyclonal antibodies for anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc20357) and β-actin (sc1616) were
obtained from Santa Cruz Biotechnology. Anti-phospho (Thr-202/204) and total ERK
antibodies were purchased from Cell Signaling Technologies. Cy3- and fluorescein-conjugated
immunoglobulin G were purchased from Jackson Immunoresearch. Fetal bovine serum was
Kennedy et al. Page 2
J Nutr. Author manuscript; available in PMC 2008 May 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
purchased from Cambrex/BioWhittaker. BRL was a gift from Glaxo Smith Kline. Isomers of
CLA (+98% pure) were purchased from Matreya. The Nucleofector and Dual Glo luciferase
(luc) kits were obtained from Amaxa and Promega, respectively. All other reagents and
chemicals were purchased from Sigma Chemical unless otherwise stated.
Culturing of human primary adipocytes
Abdominal white adipose tissue was obtained from nondiabetic females between the ages of
20 and 50 y old with a BMI ≤ 30 during abdominoplasty with consent from the Institutional
Review Board at the University of North Carolina at Greensboro. Tissue was digested using
collagenase and stromal vascular cells were isolated as previously described (11). Experimental
treatment of cultures containing ∼50% preadipocytes and ∼50% adipocytes occurred on d 12
of differentiation. Each experiment was conducted in duplicate and repeated at least 3 times
using a mixture of cells from 2−3 subjects unless otherwise indicated.
Preparation of fatty acids
Both isomers of CLA were complexed to fatty acid-free (≥98%) bovine serum albumin (BSA)
at a 4:1 molar ratio using 1 mmol/L BSA stocks.
Immunoblotting
Immunoblotting was conducted as previously described (11). To resolve PPARγ phospho-
proteins, total cell extracts (75 μg protein) were subjected to 10% SDS-PAGE
(acrylamide:bisacrylamide, 100:1, wt:wt) containing 4 mol/L urea and to electrophoresis at 80
V for 20 h as we previously described (21). Separated proteins were subsequently transferred
to polyvinylidene difluoride membranes and immunoblotted with a monoclonal PPARγ
antibody. For determining the phosphorylation status of PPARγ, a portion of the cell extracts
from BSA vehicle and CLA treatment were incubated with 20 U of calf intestinal phosphatase
(Cip) for 30 min at 37°C and for 15 min at 55°C. Subsequently, the samples were subjected to
SDS-PAGE containing urea as described above.
Immunostaining of PPARγ
Cells were cultured on coverslips for immunofluorescence microscopy and stained as described
previously (11) except for the permeabilization step. Fixed cells were permeabilized with 0.1%
Triton X-100 for 1 min on ice. Monoclonal anti-PPARγ (1:10) were incubated overnight at 4°
C. Fluorescent images were captured with a SPOT digital camera mounted on an Olympus
BX60 fluorescence microscope.
Transient transfections of human adipocytes
For measuring PPARγ activity, primary human adipocytes were transiently transfected with
the multimerized PPAR-responsive (luc) reporter construct pTK-PPRE33-luc (22) using the
Amaxa Nucleofector as previously described (21). On d 6 of differentiation, 1 × 106 cells from
a 60-mm plate were trypsinized and resuspended in 100 μL of nucleofector solution (Amaxa)
and mixed with 2 μg of pTK-PPRE3×-luc and 25 ng pRL-CMV for each sample.
Electroporation was performed using the V-33 nucleofector program (Amaxa). Cells were
replated in 96-well plates after 10 min of recovery in calcium-free RPMI media. Firefly luc
activity was measured using the Dual-Glo luc kit and normalized to Renilla luc activity from
the cotransfected control pRL-CMV vector. All luc data are presented as a ratio of firefly luc
to Renilla luc activity. We consistently obtained ∼75% transfection efficiency revealed by
parallel transfections with a green fluorescent protein reporter construct. Both adipocytes and
nonadipocytes were transfectable using this protocol based on aP2 immunostaining and 4′,6-
diamidino-phenylindole nuclear staining.
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RNA analysis
Following treatment, cultures were harvested for total RNA using Tri-Reagent according to
the manufacturer's protocol. Contaminating DNA was removed with DNAase (DNA-free,
Ambion). One microgram of RNA from each sample was used for semiquantitative RT-PCR
using the One-Step RT-PCR kit (Qiagen) as previously described in Brown et al. (10). The
gene-specific primer pairs used were previously described (10).
Lipid staining
Lipid staining of cultures of human adipocytes was conducted as previously described (10)
using Oil Red O (ORO).
[3H] 2-deoxy-glucose uptake
Newly differentiated cultures of adipocytes were incubated with BSA vehicle, 30 μmol/L cis-9,
trans-11 CLA, 30 μmol/L trans-10, cis-12 CLA, 30 μmol/L trans-10, cis-12 CLA + 1 μmol/L
BRL, or 1 μmol/L BRL in adipocyte media for 2 d. Then, for an additional 2 d, cultures were
incubated in 1 mL of serum-free basal DMEM containing 1000 mg/L D-(+)-glucose with or
without 20 pmol/L of human insulin with BSA vehicle, 30 μmol/L cis-9, trans-11 CLA, 30
μmol/L trans-10, cis-12 CLA, 30 μmol/L trans-10, cis-12 CLA + 1 μmol/L BRL, or 1 μmol/
L BRL in adipocyte media for another 2 d. Following the experimental treatments, insulin-
stimulated uptake of [3H]-2-deoxy-glucose was measured following a 90-min incubation in
the presence of 100 nmol/L human insulin as described previously (16).
Statistical analysis
Statistical analyses were performed for data in Figure 1 testing the main effects of BRL and
CLA and the interaction of the 2 (BRL × CLA) using 2-way ANOVA (JMP version 6.03, SAS
Institute). Analyses for significant differences for data in Figure 4C were conducted using 1-
way ANOVA. Student's t tests were used to compute individual pairwise comparisons of least
square means (P < 0.05). Data are expressed as the means ± SE.
Results
Trans-10, cis-12 CLA decreases the activity and increases phosphorylation of PPARγ
To determine the extent to which CLA decreased PPARγ activity, basal- and ligand-induced
activation of PPARγ activity were examined. There were no significant differences in basal
levels of PPARγ activity due to CLA treatment in the absence of BRL (Fig. 1). However,
PPARγ activity in BRL-stimulated cultures (+BRL) was lower in cultures treated with 30
μmol/L trans-10, cis-12 CLA compared with control and 30 μmol/L cis-9, trans-11 CLA-
treated cultures. The extent to which trans-10, cis-12 CLA decreased PPARγ activity (∼40%)
was comparable to that of PPARγ antagonist GW9662, which inhibited ligand-induced
PPARγ activity without affecting basal activity (data not shown).
Given the inverse relationship between PPARγ activity and its phosphorylation status (7), we
wanted to determine the kinetics of PPARγ phosphorylation during treatment with trans-10,
cis-12 CLA. Trans-10, cis-12 CLA caused a band shift in PPARγ1/2 after 24 h of treatment
(Fig. 2A). Intriguingly, robust ERK1/2 phosphorylation at 24 h accompanied the PPARγ1/2
band shift, consistent with ERK1/2's role as a donor of phosphate groups to nuclear PPARγ1/2
and with our published data demonstrating that ERK1/2 is required for CLA's suppression of
adipogenic gene expression and glucose uptake (11). However, because a PPARγ band shift
could be due to processes other than phosphorylation (e.g. by acetylation, methylation, or
sumylation), Cip was added to the cell extracts to remove phosphorylated groups. Trans-10,
cis-12 CLA-induced band shifts of PPARγ1/2 were either lowered or attenuated by phosphatase
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treatment (Fig. 2B). Taken together, these data suggest that trans-10, cis-12 CLA promotes
PPARγ and ERK phosphorylation, which contributes at least in part to CLA's isomer-specific
reduction of PPARγ activity.
Trans-10, cis-12 CLA decreases the protein levels of PPARγ
We previously demonstrated that a physiological level (e.g. 30 μmol/L) of trans-10, cis-12
CLA decreased the mRNA levels of PPARγ and several of its target genes in differentiating
cultures of human stromal vascular cells (10) and in the newly differentiated cultures of human
adipocytes (11). However, the isomer-specific impact of CLA on PPARγ protein levels in
human adipocytes is unknown. PPARγ2 protein levels were decreased after 4 d and
undetectable after 6 d of treatment with trans-10, cis-12 CLA compared with the BSA vehicle
or cis-9, trans-11 CLA-treated cultures (Fig. 3A). Consistent with these data, newly
differentiated cultures treated with 30 μmol/L trans-10, cis-12 CLA for 4 d had dramatically
less nuclear PPARγ staining compared with BSA vehicle-treated cultures (Fig. 3B). These data
demonstrate that trans-10, cis-12 CLA decreases PPARγ protein levels in an isomer-specific
manner in newly differentiated human adipocytes.
Chronic effects of a trans-10, cis-12 CLA in the presence of a PPARγ ligand
To further evaluate the antagonistic effects of trans-10, cis-12 CLA on PPARγ activity, we
examined the extent to which cosupplementation with the PPARγ agonist BRL could prevent
trans-10, cis-12 CLA suppression of adipogenic genes and proteins, glucose uptake, and TG
accumulation. Trans-10, cis-12 CLA decreased the mRNA (Fig. 4A) and protein (Fig. 4B)
levels of PPARγ, aP2, LPL, and GLUT4 compared with BSA vehicle controls or cis-9,
trans-11 CLA. Although BRL cosupplementation prevented CLA-mediated reductions in aP2,
LPL, and PLIN gene expression, it did not prevent CLA suppression of PPARγ2 or GLUT4
mRNA levels (Fig. 4A). Consistent with these data, BRL cosupplementation prevented CLA
suppression of aP2 protein expression but did not prevent CLA suppression of PPARγ or
GLUT4 protein levels (Fig. 4B).
CLA isomer-specific reduction of insulin-stimulated glucose uptake (Fig. 4C) or TG
accumulation (Fig. 4D) was not prevented by cosupplementation with BRL. Collectively, these
data demonstrate that trans-10, cis-12 CLA chronically suppresses adipogenic gene and protein
expression, glucose uptake, and TG content, which are only partially prevented by a PPARγ
ligand.
Effects of withdrawal from trans-10, cis-12 CLA in presence of a PPARγ ligand
Next, we wanted to determine whether the delipidating effects of CLA could be rescued by
CLA withdrawal in the absence or presence of a PPARγ ligand. Surprisingly, withdrawal of
trans-10, cis-12 CLA treatment for 2 wk did not restore the mRNA levels of LPL, PLIN, or
GLUT4 gene (group 1, Fig. 5A) or the protein levels of PPARγ or GLUT4 (group 1, Fig. 5B).
Interestingly, the pattern of gene and protein expression in group 1 was almost identical to that
of the cultures treated for 1 wk with trans-10, cis-12 CLA (Fig. 4), indicating the effects of
CLA were sustained over 2 wk. Consistent with these gene and protein data, cultures treated
with trans-10, cis-12 CLA had less stainable TG 2 wk after withdrawal (group 1, Fig. 5C)
compared with controls.
BRL supplementation for 2 wk following CLA withdrawal rescued PPARγ, aP2, and LPL gene
expression compared with BSA vehicle- or cis-9, trans-11 CLA-treated cultures, whereas PLIN
and GLUT4 were partially rescued (Group 2, Fig. 5A). BRL supplementation for 2 wk
following CLA withdrawal reversed or attenuated trans-10, cis-12 CLA suppression of aP2
and GLUT4 protein levels, respectively, compared with cultures not receiving BRL for 2 wk
(group 1). Although CLA-treated cultures supplemented for 2 wk with BRL (group 2) had
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more PPARγ protein compared with those not receiving BRL for 2 wk (group 1), PPARγ protein
levels did not return to the levels of the BSA vehicle- or cis-9, trans-11 CLA-treated cultures.
Similarly, supplementation of cultures with BRL for 2 wk during CLA withdrawal (group 2)
increased the TG content of cultures treated with trans-10, cis-12 CLA compared with cultures
not receiving BRL during withdrawal (group 1). Interestingly, BRL was only effective in
preventing delipidation when it was cosupplemented with CLA and then supplemented for
another 2 wk following CLA withdrawal (group 2, Fig. 5C). Taken together, these data
demonstrate that trans-10, cis-12 CLA-mediated delipidation persists after CLA withdrawal
and is relatively refractory to supplementation with a PPARγ ligand unless the ligand is
supplemented during and after CLA treatment.
Discussion
The PPARγ agonist rosiglitazone has been demonstrated to prevent or attenuate inflammation,
lipodystrophy, and insulin resistance in mice fed a crude mixture of CLA isomers (e.g.
primarily cis-9, trans-11 CLA and trans-10, cis-12 CLA) (19,20). These data suggest an
antagonism between one or both CLA isomers and PPARγ. However, the isomer-specific
mechanism by which CLA suppresses the activity of PPARγ in human adipocytes remains
unknown. We demonstrate in this article that trans-10, cis-12, but not cis-9, trans-11, CLA
attenuates ligand-induced activation of PPARγ (Fig. 1), possibly via phosphorylation of
PPARγ by ERK1/2 (Fig. 2). Inactivation of PPARγ leads to suppression of protein and mRNA
levels of PPARγ and several of its target genes in newly differentiated human adipocytes (Figs.
3, 4, 5). BRL cosupplementation did not prevent insulin resistance caused by trans-10, cis-12
CLA (Fig. 4). Furthermore, we show that trans-10, cis-12 CLA-mediated suppression of TG
accumulation does not return to control levels following CLA withdrawal or by
supplementation with a PPARγ agonist following CLA treatment (Fig. 5). Only BRL
cosupplementation followed by 2 wk of BRL supplementation restored the TG content of
trans-10, cis-12 CLA-treated cultures to control levels. Taken together, these data provide
further support for the concept that CLA's antiadipogenic effects in humans are due to the
trans-10, cis-12 isomer and not the cis-9, trans-11 isomer and are directly linked to the
suppression of PPARγ activity, adipogenic gene and protein expression, insulin-stimulated
glucose uptake, and TG content, which appears to be due in part to an antagonism of ligand-
mediated activation of PPARγ.
Potential mechanisms explaining the isomer-specific attenuation of PPARγ activity by CLA
are shown in our working model (Fig. 6). We propose that trans-10, cis-12 CLA, a metabolite,
or a signal activated by CLA suppresses PPARγ activity by: 1) phosphorylating PPARγ via
activation ERK1/2; 2) inhibiting ligand activation and heterodimer formation with RXR; or
3) impairing DNA binding of the PPRE to target genes, thereby decreasing adipogenic gene
transcription, insulin-stimulated glucose uptake, and TG synthesis.
PPARγ phosphorylation
Support for the first 2 mechanisms comes from our discovery that trans-10, cis-12 CLA
suppresses adipogenic gene expression and metabolism through activation of ERK1/2 (11) and
NFκB (16). Reports demonstrating that NFκB (23–27) and MAPK (28–30) activation hinders
PPARγ DNA-binding affinity or transcriptional activation provides a potential mechanism by
which trans-10, cis-12 CLA suppresses the expression of PPARγ target genes, leading to
delipidation. ERK1/2 activates NFκB (31) and inactivates PPARγ (32), resulting in its
ubiquination and proteosome degradation (33). Further support comes from studies showing
that PPARγ agonists attenuate cytokine-mediated inflammation by suppressing NFκB and/or
MAPK signaling (34–37). Clearly, the activity of PPARγ is regulated by its phosphorylation
status via phosphatases and kinases (33). Indeed, the phosphorylation of PPARγ at a consensus
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MAPK site within its A/B domain (e.g. Ser-112) by ERK1/ 2 or c-Jun-NH2-terminal kinase
reduces its transcriptional activation potential, leading to insulin resistance and/or decreased
adipogenesis (8,28–30,32,37,38). Interestingly, we previously reported that the MEK/ERK
inhibitor U0126 blocked trans-10, cis-12 CLA suppression of adipogenic genes and glucose
and fatty acid uptake (11). Consistent with these data, we found that trans-10, cis-12 CLA
simultaneously increased the phosphorylation of ERK1/2 and PPARγ (Fig. 2A). Based on these
data, our working hypothesis is that trans-10, cis-12 CLA antagonizes PPARγ's activity acutely
and PPARγ expression chronically in adipocytes via NFκB and ERK1/2 activation, leading to
decreased glucose and fatty acid uptake and TG synthesis.
Ligand binding
CLA may also compete with endogenous (i.e. unsaturated fatty acids) or exogenous (i.e.
rosiglitazone-BRL) ligands for activation of PPARγ. Low affinity PPARγ ligands such as
PUFA increase PPARγ activity and target gene expression (39). Several CLA isomers,
including cis-9, trans-11 CLA, have been shown to be ligands for PPARγ (13,40) or its partner
RXR (39). Consistent with the reported antagonism between PPARγ and inflammation, cis-9,
trans-11 CLA has been shown to suppress NFκB activation and inflammatory cytokine
production by lipopolysaccharide in dendritic cells (41) and in white adipose tissue of obese
mice (42). However, we found that cosupplementation of trans-10, cis-12 CLA-treated cultures
with up to 30 μmol/L cis-9, trans-11 CLA did not reverse insulin resistance or adipogenic gene
expression (data not shown). In contrast, Granlund et al. (13) demonstrated that both cis-9,
trans-11 CLA and trans-10, cis-12 CLA decreased the activity of a darglitazone-stimulated,
LXRα-PPRE-LUC reporter in a dose-dependent manner up to 25 μmol/L in COS-1 cells and
3T3-L1 cells. We have also demonstrated in 3T3-L1 that both CLA isomers antagonize ligand-
induced activation of PPARγ (10). Alternatively, CLA phosphorylation of PPARγ in the A/B
domain could reduce PPARγ affinity for ligand and/or cofactor recruitment (33).
Transcriptional activation
Another possible mechanism by which CLA reduces PPARγ activity is by impairing DNA
binding of the PPARγ/RXR heterodimer itself to the PPRE in target genes, thereby decreasing
transcriptional activation. Conceptually, this would lead to decreased lipogenesis and TG
accumulation. However, chromatin immunoprecipitation studies are needed to support this
speculative mode of action of CLA.
One possible explanation for the long-term effects of CLA following withdrawal could be that
CLA accumulates within the phospholipid and neutral lipid fractions of the cell, as we have
previously shown for both isomers (10). Thus, CLA could continue to antagonize PPARγ/RXR
activity following withdrawal, thereby impacting endogenous ligand production,
phosphorylation, and/or directly interfering with their transcriptional activation.
In summary, although cosupplementation with BRL, a high affinity ligand for PPARγ,
generally prevented or attenuated trans-10, cis-12 CLA suppression of adipogenic gene and
protein expression and TG content, it did not prevent CLA's suppression of a PPARγ reporter
construct or insulin-stimulated glucose up-take. Furthermore, BRL supplementation for 2 wk
after CLA withdrawal did not completely rescue its antiadipogenic and TG-lowering effects.
Taken together, these data suggest that trans-10, cis-12 CLA may decrease PPARγ activity
acutely by increasing PPARγ phosphorylation via ERK1/2 and chronically by decreasing
PPARγ transcription, thereby decreasing the amount PPARγ available for ligand binding,
leading to the suppression of insulin-stimulated glucose uptake and TG accumulation.
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FIGURE 1.
Trans-10, cis-12 CLA blocks ligand-induced activation of PPARγ in human adipocytes.
Cultures of newly differentiated human adipocytes were transfected on d 6 with pTK-PPRE33-
luc and pRL-CMV. Twenty four hours later, transfected cells were treated with dimethyl
sulfoxide vehicle control (C), 30 μmol/L trans-10, cis-12 CLA, or 30 μmol/L cis-9, trans-11
CLA in the absence or presence of 0.1 μmol/L BRL for 24 h. Values are means ± SEM, n = 3.
Means without a common letter differ, P < 0.05.
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FIGURE 2.
Trans-10, cis-CLA increases PPARγ phosphorylation in human adipocytes. (A) Cultures of
newly differentiated human adipocytes were serum starved for 24 h and then treated without
(0) or with 30 μmol/L trans-10, cis-12 CLA (10) for 2, 4, 8, or 24 h. Subsequently, cell extracts
were harvested, proteins separated by SDS-PAGE urea, and immunoblotted for the
phosphorylated and unphosphorylated forms of PPARγ1/2, ERK1/2, and GAPDH (load
control). (B) Cultures were treated for 24 h with BSA vehicle or 30 μmol/L trans-10, cis-12
CLA (10). A portion of the cell extracts from BSA vehicle and CLA treatment were incubated
with Cip. Proteins were separated with SDS-PAGE urea and probed with antibodies targeting
PPARγ1/2 and GAPDH. Data in A and B are representative of 2 independent experiments.
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FIGURE 3.
Trans-10, cis-12 CLA decreases PPARγ protein levels in human adipocytes. (A) Cultures of
newly differentiated human adipocytes were treated with BSA vehicle (B), 30 μmol/L cis-9,
trans-11 CLA (9), or 30 μmol/L trans-10, cis-12 CLA (10) for 2, 4, 6, or 8 d. Cells extracts
were immunoblotted for PPARγ. To identify PPARγ1/2 in cultures of human adipocytes, cell
extracts from 3T3-L1 adipocytes (mouse) were isolated and immunoblotted for PPARγ. A 3rd
band was identified in human adipocytes and labeled as nonspecific (NS). (B) Cultures were
treated with BSA vehicle (B) or 30 μmmol/L trans-10, cis-12 CLA (10) for 4 d. PPARγ was
detected using immunofluorescence microscopy. Data are representative of 2 independent
experiments.
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FIGURE 4.
Trans-10, cis-12 CLA antagonizes ligand-activated PPARγ expression, glucose uptake, and
TG accumulation in human adipocytes. (A) Cultures of newly differentiated human adipocytes
were treated for 1 wk with either BSA vehicle (B), 30 μmol/L cis-9, trans-11 CLA (9), 30
μmol/L trans-10, cis-12 CLA (10), or 30 μmol/L trans-10, cis-12 CLA + 1 μmol/L BRL (10*)
and then harvested. RNA was isolated and the mRNA levels of PPARγ2, aP2, LPL, PLIN, and
Glut 4 were measured using semiquantitative RT-PCR. 18S ribosomal RNA was used as an
internal control. (B) Cultures were treated as in A for 1 wk and then cell extracts were isolated
and immunoblotted for PPARγ, aP2, Glut4, and β-actin. (C) Cultures were treated as in A for
4 d and then insulin-stimulated uptake of [3H]-2-deoxyglucose was measured. Values are
means ± SEM; n = 6. Means without a common letter differ, P < 0.05. (D) Cultures were treated
as in A for 1 wk and then stained with ORO and phase-contrast photo-micrographs were taken
using an Olympus inverted microscope with a 10× objective. Data in A, B,,and D are
representative of 2−3 independent experiments.
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FIGURE 5.
Effects of withdrawal of trans-10, cis-12 CLA in the presence of a PPARγ ligand in human
adipocytes. Cultures of newly differentiated human adipocytes were treated for 1 wk with either
BSA vehicle (B), 30 μmol/L cis-9, trans-11 CLA (9), 30 μmol/L trans-10, cis-12 CLA (10),
or 30 μmol/L trans-10, cis-12 CLA + 1 umol/L BRL (10*) and then had their treatments
withdrawn for 2 wk (group 1, -BRL), or were treated with 1 μmol/L BRL for 2 wk during CLA
withdrawal (group 2, +BRL). (A) RNA was isolated and the mRNA levels of PPARγ2, aP2,
LPL, PLIN, and Glut4 were measured using semiquantitative RT-PCR. 18S ribosomal RNA
was used as an internal control. (B) Cell extracts were isolated and immuno-blotted for
PPARγ, aP2, Glut4, and β-actin. (C) Cultures were stained with ORO and phase-contrast
photomicrographs were taken using an Olympus inverted microscope with a 10× objective.
Data are representative of 2−3 independent experiments.
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FIGURE 6.
Working model CLA, metabolites, or signals suppress PPARγ activity by: 1) phosphorylating
PPARγ via activation of NFκB and ERK1/2; 2) inhibiting ligand activation and/or heterodimer
formation with RXR; or 3) impairing transcriptional activation of target genes, thereby
decreasing TG synthesis.
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